NCT04787328 is a Phase 2 clinical trial of HA121-28 tablets in Medullary Thyroid Carcinoma, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Who is sponsoring NCT04787328?

NCT04787328 is sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

What drugs are being tested in NCT04787328?

Interventions in NCT04787328: HA121-28 tablets.

What condition does NCT04787328 study?

NCT04787328 studies Medullary Thyroid Carcinoma.

Is NCT04787328 still recruiting?

NCT04787328 is currently status unknown. Last updated 7 February 2022.

Last reviewed 2022-02-07 · How we verify

NCT04787328

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)

Status unknown Phase 2 Last updated 7 February 2022

What this trial tests

Phase 2 trial testing HA121-28 tablets in Medullary Thyroid Carcinoma in 30 participants. Status unknown.

Timeline

13 July 2021

Primary endpoint
1 March 2023

1 March 2025

Quick facts

Lead sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	13 July 2021
Primary completion	1 March 2023
Estimated completion	1 March 2025
Sites	13 locations across China

Drugs / interventions tested

HA121-28 tablets — full drug profile →

Conditions studied

Medullary Thyroid Carcinoma — all drugs for Medullary Thyroid Carcinoma →

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Medullary Thyroid Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Objective remission rate (ORR)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause,whichever came first, assessed up to 60 months
assessed approximately every 8 weeks or 12 weeks based on the treatment cycle

Sponsor's own description

This is a single-arm, open-label, multicenter study designed to evaluate the preliminary antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in patients with medullary thyroid cancer (MTC).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Metastatic medullary thyroid carcinoma: a new way forward.
Angelousi A, Hayes AR, Chatzellis E, Kaltsas GA, et al · · 2022 · cited 30× · PMID 35521769 · DOI 10.1530/erc-21-0368
The Role of the Kinase Inhibitors in Thyroid Cancers.
Cuomo F, Giani C, Cobellis G. · · 2022 · cited 18× · PMID 35631627 · DOI 10.3390/pharmaceutics14051040
Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
Clark L, Fisher G, Brook S, Patel S, et al · · 2023 · cited 6× · PMID 38201460 · DOI 10.3390/cancers16010031
The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M, Cremaschi V, Alberti A, Vodopivec Kuri DM, et al · · 2023 · cited 6× · PMID 37979019 · DOI 10.1007/s11864-023-01145-5
Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial.
Liu Y, Li X, Zhang M, Men Y, et al · · 2025 · PMID 39876990 · DOI 10.2147/dddt.s484310

Verify or expand the search:

Other trials of HA121-28 tablets

Trials testing the same drug.

NCT04784520 — A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer · Phase 2 · terminated
NCT03994484 — Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets · Phase 1 · unknown

Other recruiting trials for Medullary Thyroid Carcinoma

Currently open trials in the same condition.

NCT07383246 — CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC · Phase 3 · recruiting
NCT07138716 — Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC · NA · recruiting

Other CSPC ZhongQi Pharmaceutical Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07532655 — A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants · Phase 1 · not yet recruiting
NCT07412353 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 · Phase 1 · recruiting
NCT07282509 — Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of · Phase 1, PHASE2 · not yet recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07241936 — A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04787328 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Last refreshed: 7 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04787328.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing